Benin vs Guinea: Average cost of drugs for extensively drug-resistant tuberculosis
Benin
6,274 constant 2022 US$
in 2024
Guinea
5,356 constant 2022 US$
in 2024
Benin rank
6th
Guinea rank
9th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Benin
- Guinea
How they compare
Benin currently reports 6,274 constant 2022 US$ against 5,356 constant 2022 US$ in Guinea, a difference of 918 constant 2022 US$.
That makes Benin's figure about 1.2 times Guinea's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Guinea ahead.
Benin ranks 6th and Guinea ranks 9th of 56 countries.
Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Benin | Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,550 constant 2022 US$ | 8,964 constant 2022 US$ | 3,414 constant 2022 US$ | Guinea |
| 2020s | 6,274 constant 2022 US$ | 8,060 constant 2022 US$ | 1,786 constant 2022 US$ | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Benin or Guinea?
- Benin, at 6,274 constant 2022 US$ against 5,356 constant 2022 US$ in Guinea as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Benin and Guinea?
- 918 constant 2022 US$, with Benin ahead.
- How many years of comparable data are there for Benin and Guinea?
- 6 years are reported by both, from 2019 to 2024.
- How do Benin and Guinea rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Benin ranks 6th and Guinea ranks 9th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.